Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next- generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Associat ...